Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
166 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dementia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Dementia - Pipeline Review, H1 2015', provides an overview of the Dementia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dementia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Dementia Overview 8 Therapeutics Development 9 Pipeline Products for Dementia - Overview 9 Pipeline Products for Dementia - Comparative Analysis 10 Dementia - Therapeutics under Development by Companies 11 Dementia - Therapeutics under Investigation by Universities/Institutes 14 Dementia - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Dementia - Products under Development by Companies 19 Dementia - Products under Investigation by Universities/Institutes 22 Dementia - Companies Involved in Therapeutics Development 23 Actinogen Limited 23 Alector LLC 24 AlzProtect SAS 25 BioArctic Neuroscience AB 26 Biogen Idec Inc. 27 Biotie Therapies Corp. 28 Bristol-Myers Squibb Company 29 Chase Pharmaceuticals Corporation 30 Chronos Therapeutics Limited 31 Daewoong Pharmaceutical Co., Ltd. 32 Echo Pharmaceuticals B.V. 33 Eisai Co., Ltd. 34 FORUM Pharmaceuticals Inc. 35 Hyundai Pharmaceutical Co., Ltd. 36 Ildong Pharmaceutical Co., Ltd. 37 IMMD Inc. 38 ImStar Therapeutics Inc. 39 Integrative Research Laboratories Sweden AB 40 Intellect Neurosciences, Inc. 41 Intra-Cellular Therapies, Inc. 42 Neurimmune Holding AG 43 Oryzon Genomics S.A. 44 Otsuka Holdings Co., Ltd. 45 Pacific Northwest Biotechnology, LLC 46 ProteoTech, Inc. 47 SK Chemicals Co., Ltd. 48 Stelic Institute & Co. 49 Sumitomo Dainippon Pharma Co., Ltd. 50 Sylentis S.A. 51 TauRx Therapeutics Ltd. 52 Tautatis Incorporated 53 Varinel, Inc. 54 WhanIn Pharmaceutical Co., Ltd. 55 Dementia - Therapeutics Assessment 56 Assessment by Monotherapy Products 56 Assessment by Target 57 Assessment by Mechanism of Action 60 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 Antisense Oligonucleotide to Inhibit microRNA for Neurology - Drug Profile 66 aripiprazole - Drug Profile 67 AVCRI-104P3 - Drug Profile 70 AZP-2006 - Drug Profile 71 brexpiprazole - Drug Profile 73 choline alfoscerate SR - Drug Profile 75 CPC-201 - Drug Profile 76 CPC-252 - Drug Profile 77 dehydroevodiamine hydrochloride - Drug Profile 78 dronabinol - Drug Profile 79 Drugs for Dementia - Drug Profile 81 Drugs to Agonize c-MET for Dementia - Drug Profile 82 Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 83 DWJ-1365 - Drug Profile 84 E-2609 - Drug Profile 85 encenicline hydrochloride - Drug Profile 86 FRM-0334 - Drug Profile 89 GIBH-130 - Drug Profile 91 gugulipid - Drug Profile 92 IIPP-1 - Drug Profile 93 IMD-4482 - Drug Profile 94 IPN-007 - Drug Profile 95 IRL-752 - Drug Profile 96 ITI-007 - Drug Profile 97 KR-12 - Drug Profile 99 Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile 100 Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 101 NAT - Drug Profile 102 NI-205 - Drug Profile 103 NI-308 - Drug Profile 104 NNC-269100 - Drug Profile 105 OG-635 - Drug Profile 106 PD-0805 - Drug Profile 107 PD-61W3 - Drug Profile 108 PD-61W3 Backup - Drug Profile 109 Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 110 PST-900 - Drug Profile 111 RDC-5 - Drug Profile 112 RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 114 SID-111 - Drug Profile 115 Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 116 Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 117 Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 118 Small Molecules to Inhibit LSD-1 And MAO-B for Neurodegenerative Diseases - Drug Profile 119 Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile 120 SYN-120 - Drug Profile 121 Synthetic Peptides for Neurological Disorders - Drug Profile 122 TAK-070 - Drug Profile 123 TauC-3 - Drug Profile 124 TPI-287 - Drug Profile 125 TRx-0237 - Drug Profile 127 TTT-3002 - Drug Profile 129 UE-2343 - Drug Profile 130 VAR-10100 - Drug Profile 131 WIB-1001C - Drug Profile 132 zonisamide - Drug Profile 133 Dementia - Recent Pipeline Updates 134 Dementia - Dormant Projects 150 Dementia - Discontinued Products 152 Dementia - Product Development Milestones 153 Featured News & Press Releases 153 Appendix 161 Methodology 161 Coverage 161 Secondary Research 161 Primary Research 161 Expert Panel Validation 161 Contact Us 162 Disclaimer 162
List of Tables Number of Products under Development for Dementia, H1 2015 13 Number of Products under Development for Dementia - Comparative Analysis, H1 2015 14 Number of Products under Development by Companies, H1 2015 16 Number of Products under Development by Companies, H1 2015 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H1 2015 19 Comparative Analysis by Late Stage Development, H1 2015 20 Comparative Analysis by Clinical Stage Development, H1 2015 21 Comparative Analysis by Early Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 Dementia - Pipeline by Actinogen Limited, H1 2015 27 Dementia - Pipeline by Alector LLC, H1 2015 28 Dementia - Pipeline by AlzProtect SAS, H1 2015 29 Dementia - Pipeline by BioArctic Neuroscience AB, H1 2015 30 Dementia - Pipeline by Biogen Idec Inc., H1 2015 31 Dementia - Pipeline by Biotie Therapies Corp., H1 2015 32 Dementia - Pipeline by Bristol-Myers Squibb Company, H1 2015 33 Dementia - Pipeline by Chase Pharmaceuticals Corporation, H1 2015 34 Dementia - Pipeline by Chronos Therapeutics Limited, H1 2015 35 Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 36 Dementia - Pipeline by Echo Pharmaceuticals B.V., H1 2015 37 Dementia - Pipeline by Eisai Co., Ltd., H1 2015 38 Dementia - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 39 Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2015 40 Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 41 Dementia - Pipeline by IMMD Inc., H1 2015 42 Dementia - Pipeline by ImStar Therapeutics Inc., H1 2015 43 Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2015 44 Dementia - Pipeline by Intellect Neurosciences, Inc., H1 2015 45 Dementia - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 46 Dementia - Pipeline by Neurimmune Holding AG, H1 2015 47 Dementia - Pipeline by Oryzon Genomics S.A., H1 2015 48 Dementia - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 49 Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H1 2015 50 Dementia - Pipeline by ProteoTech, Inc., H1 2015 51 Dementia - Pipeline by SK Chemicals Co., Ltd., H1 2015 52 Dementia - Pipeline by Stelic Institute & Co., H1 2015 53 Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 54 Dementia - Pipeline by Sylentis S.A., H1 2015 55 Dementia - Pipeline by TauRx Therapeutics Ltd., H1 2015 56 Dementia - Pipeline by Tautatis Incorporated, H1 2015 57 Dementia - Pipeline by Varinel, Inc., H1 2015 58 Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 59 Assessment by Monotherapy Products, H1 2015 60 Number of Products by Stage and Target, H1 2015 62 Number of Products by Stage and Mechanism of Action, H1 2015 65 Number of Products by Stage and Route of Administration, H1 2015 67 Number of Products by Stage and Molecule Type, H1 2015 69 Dementia Therapeutics - Recent Pipeline Updates, H1 2015 138 Dementia - Dormant Projects, H1 2015 154 Dementia - Discontinued Products, H1 2015 156
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
